DIFFERENCES BETWEEN CALCIUM-ANTAGONISTS - DURATION OF ACTION AND TROUGH TO PEAK RATIO

被引:35
作者
MEREDITH, PA
REID, JL
机构
[1] Department of Medicine and Therapeutics, Gardiner Institute, Western Infirmary, Glasgow
关键词
AMBULATORY BLOOD PRESSURE; PHARMACOKINETICS; DURATION OF ACTION; LACIDIPINE; BLOOD PRESSURE VARIABILITY; FOOD-AND-DRUG-ADMINISTRATION GUIDELINES; TROUGH TO PEAK RATIO;
D O I
10.1097/00004872-199303001-00004
中图分类号
R6 [外科学];
学科分类号
1002 ; 100210 ;
摘要
Comparison of first- and second-generation calcium antagonists: Despite their diversity of structure, the first-generation calcium antagonists nifedipine, verapamil and diltiazem all have a short elimination half-life and a relatively short duration of action. In contrast, there appears to be wide diversity in these properties among the newer calcium antagonists, which are mostly dihydropyridines. The longer half-life and physicochemical properties of some of the newer agents allow full 24-h blood pressure control. Duration of action of lacidipine: Taken only once a day, lacidipine has proved as potent an antihypertensive agent as slow-release nifedipine administered twice a day. Lacidipine produces a satisfactory fall in blood pressure not only during waking hours but also during sleep at night, as shown by 24-h ambulatory monitoring. Moreover, this blood pressure fall is obtained without any reflex tachycardia or associated side effects. Compared with patients treated with placebo, systolic and mean arterial blood pressure variability (standard deviation) is reduced by lacidipine treatment. Conclusions: Control of blood pressure using lacidipine once a day meets the criteria proposed by the Unitd States Food and Drugs Adminstration for antihypertensive drug efficacy and duration of action.
引用
收藏
页码:S21 / S26
页数:6
相关论文
共 21 条
[1]   NIFEDIPINE - INDIVIDUAL-RESPONSES AND CONCENTRATION-EFFECT RELATIONSHIPS [J].
DONNELLY, R ;
ELLIOTT, HL ;
MEREDITH, PA ;
KELMAN, AW ;
REID, JL .
HYPERTENSION, 1988, 12 (04) :443-449
[2]  
FLECKENSTEIN A, 1983, CIRC RES S11, V52, P1
[3]   FUNCTIONAL INTERACTION OF LACIDIPINE WITH CALCIUM CHANNELS IN VASCULAR SMOOTH-MUSCLE [J].
GODFRAIND, T ;
SALOMONE, S .
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY, 1991, 18 :S1-S6
[4]   RATE OF INCREASE IN THE PLASMA-CONCENTRATION OF NIFEDIPINE AS A MAJOR DETERMINANT OF ITS HEMODYNAMIC-EFFECTS IN HUMANS [J].
KLEINBLOESEM, CH ;
VANBRUMMELEN, P ;
DANHOF, M ;
FABER, H ;
URQUHART, J ;
BREIMER, DD .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1987, 41 (01) :26-30
[5]   NIFEDIPINE - RELATIONSHIP BETWEEN PHARMACOKINETICS AND PHARMACODYNAMICS [J].
KLEINBLOESEM, CH ;
VANBRUMMELEN, P ;
BREIMER, DD .
CLINICAL PHARMACOKINETICS, 1987, 12 (01) :12-29
[6]  
LEDERBALLEPEDER.O, 1978, EUR J CLIN PHARMACOL, V14, P374
[8]   PREDICTION OF RESPONSE TO ANTIHYPERTENSIVE THERAPY WITH ENALAPRIL AND NIFEDIPINE [J].
MEREDITH, PA ;
ELLIOTT, HL ;
DONNELLY, R ;
REID, JL .
JOURNAL OF HYPERTENSION, 1989, 7 :S252-S253
[9]   VERAPAMIL PHARMACOKINETICS AND APPARENT HEPATIC AND RENAL BLOOD-FLOW [J].
MEREDITH, PA ;
ELLIOTT, HL ;
PASANISI, F ;
KELMAN, AW ;
SUMNER, DJ ;
REID, JL .
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 1985, 20 (02) :101-106
[10]  
MEREDITH PA, 1987, J HYPERTENS S5, V5, pS215